

## Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

Kalliopi Domvri<sup>1</sup>, Kaid Darwiche<sup>2</sup>, Paul Zarogoulidis<sup>1</sup>, Konstantinos Zarogoulidis<sup>1</sup>

<sup>1</sup>Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; <sup>2</sup>University Pulmonary Department-Interventional Unit, "Ruhrland Klinik", University of Duisburg-Essen, Essen, Germany

Correspondence to: Paul Zarogoulidis, M.D, Ph.D. Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Email: pzarog@hotmail.com.



Submitted Nov 16, 2012. Accepted for publication Dec 17, 2012.

doi: 10.3978/j.issn.2218-6751.2012.12.06

Scan to your mobile device or view this article at: <http://www.tlcr.org/article/view/820/2050>

Lung cancer is still the leading cause of death in the United States and worldwide (1). The 5-year survival rate is still only 14% implying the need for new treatments (2). According to the National Cancer Institute Office of Cancer Genomics, for the facilitation of personalized cancer medicine (PCM), based on genetic aberrations which exist in human malignancies, three goals have been established; first, enhancement of the understanding of the molecular mechanisms of cancer; second, the acceleration of genomic science and technology development; and third, translation of genomic data to improve cancer prevention, early detection, diagnosis, and treatment (3).

Thus, it is a fact that molecular profiling has been added in the evolving treatment of lung cancer and has been considered for predicting response to selected therapies. Besides, 85% of all lung cancers are categorized as non-small cell lung cancer (NSCLC) confirming the importance of understanding the molecular profile of this type of lung cancer (4). It is known that clinical research in the treatment of NSCLC concerns two goals, cytotoxic agents such as platinum compounds and tubulin inhibitors and targeted agents by interrupting the signaling pathways responsible for cell proliferation and survival. Furthermore, the identification of mutations and aberrations that concern NSCLC molecular pathways has enabled a personalized medicine approach to treatment.

Epidermal growth factor receptor (EGFR) signaling is one of the major targets of NSCLC treatment, considering that EGFR overexpression is found in approximately 40-80% of the patients (5). Several research groups identified EGFR gene mutations as predictive factors for drug sensitivity (6-8). EGFR mutations have been identified

in larger numbers in Asians, women, non-smokers, and patients with adenocarcinoma, groups. These populations match the highly gefitinib-sensitive clinical subset (9).

Moreover, EGFR which has been clinically investigated for more than a decade, activates 2 major pathways in solid tumors, the RAS/RAF/MEK/MARK and the PI3K/AKT/mTOR pathway, which induce cancer cell proliferation, cell growth, invasion, metastatic spread, apoptosis, and tumor angiogenesis (10).

More specifically, EGFR tyrosine kinase inhibitors target the intracellular tyrosine kinase (TK) domain of EGFR, blocking the downstream signaling of the receptor (10). These include gefitinib (Iressa; AstraZeneca, Wilmington, DE), erlotinib (Tarceva; Genentech, South San Francisco, CA), which have been established as first-line therapy for NSCLC patients whose tumors harbor an EGF receptor gene mutation, including exon 19 deletion and exon 21 L858R (11). Although plenty clinical trials showed good response rates and PFS (12,13) in NSCLC patients with EGFR mutations, acquired resistance in these patients responsive to EGFR-TKIs is a major clinical problem (14). Moreover, an anti-EGFR monoclonal antibody, cetuximab (chimeric human-mouse anti-EGFR) (15) has been used in several clinical trials resulting in good tolerability (16).

Recently, acquired resistance has been reported to include mechanisms such as secondary mutation of the EGFR gene, amplification of the MET gene, and overexpression of hepatocyte growth factor (HGF) (14). Moreover, a meta-analysis of studies in advanced NSCLC demonstrated that k-RAS mutations are highly specific negative predictors of response (de-novo resistance) to single-agent EGFR TKIs (17). However, other groups reported that the clinical usefulness of

KRAS mutation as a selection marker either for EGFR-TKIs or cetuximab sensitivity in NSCLC is limited (18,19).

As a result novel compounds have been developed such as irreversible EGFR-TKIs to overcome resistance. These new pharmaceutical agents bind irreversibly to EGFR tyrosine kinase and include neratinib or HKI-272, PF00299804, and afatinib or BIBW 2992 which are currently being evaluated in clinical development for NSCLC (20).

Other studies in Phase I and Phase II trials have demonstrated the use of anti-EGFR TKIs in combination with radiation or concurrent chemoradiation for stage III NSCLC to be feasible but still remains to be further determined (21-23).

The PI3K/AKT/mTOR pathway includes Akt, one of the most frequently activated protein kinases in human cancer (24). Drugs interfering with the mTOR pathway includes rapamycin (sirolimus), cell cycle inhibitor (CCD)-779 (temsirolimus) and RAD001 (everolimus) (25). Although mTOR inhibitors such as everolimus in combination with EGFR inhibitors appear to be well tolerated, with some evidence suggesting antitumor activity (26), optimization of the therapeutic impact of mTOR inhibitors still remain to be clarified when reliable predictive factors will be identified. In addition, another study indicated that transient blockade of PI3K/Akt pathway might overcome EGFR TKIs resistance and restore sensitivity to agents well tolerated, thereby providing clinical benefit (27).

Another active research field in NSCLC is the discovery of therapies that target angiogenesis. Vascular endothelial growth factor (VEGF) pathway includes monoclonal antibodies against VEGF such as bevacizumab which has been approved for the treatment of metastatic non-squamous NSCLC in combination with carboplatin and paclitaxel and showed increased survival (28), VEGF receptors such as aflibercept and also small molecule TKIs such as sunitinib and sorafenib that target the TK domain of VEGF receptor (29). There are also other agents that are under clinical development concerning the antiangiogenic pathway. Predictive biomarkers of response to antiangiogenic therapy and the mechanisms of resistance to these agents are still under investigation. The latest goal of the researchers is the evaluation of antiangiogenics in combination with radiotherapy. Data do not support the combination of bevacizumab and radiation (30).

Other targets include MET oncogene or EML4-ALK (anaplastic lymphoma kinase) fusion which is a rare abnormality, appeared in 4-5% of NSCLC patients (31). The Met and ALK inhibitor crizotinib in the first-in-man

phase I study in patients with EML4-ALK fusion showed good tolerability with rapid, durable responses (32).

At this point EGFR gene mutations used as predictive factors is the best accomplishment achieved so far by the researchers. Their efforts are focused on identifying other molecular signatures that could be predictive of response. Indeed, targeted therapies have revolutionized the area of NSCLC treatment. Pharmacogenetics and pharmacogenomics will be ultimately leading to drug prescription based on a patient's individual genetic and molecular profile.

## Acknowledgements

*Disclosure:* The authors declare no conflict of interest.

## References

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer J Clin* 2010;60:277-300.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. *N Engl J Med* 2004;350:379-92.
3. Tran B, Dancey JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. *J Clin Oncol* 2012;30:647-60.
4. Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. *Clin Lung Cancer* 2004;6:S24-9.
5. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006;441:424-30.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.
7. Sugio K, Uramoto H, Onitsuka T, et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. *Lung Cancer* 2009;64:314-8.
8. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naïve non-small-cell lung cancer receiving first-line gefitinib monotherapy. *J Clin Oncol* 2008;26:2745-53.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-8.
10. Janku F, Garrido-Laguna I, Petruzella LB, et al. Novel

- therapeutic targets in non-small cell lung cancer. *J Thorac Oncol* 2011;6:1601-12.
11. Rosell R, Viteri S, Molina MA, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. *Curr Opin Oncol* 2010;22:112-20.
  12. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. *Lung Cancer* 2011;74:469-73.
  13. Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. *Int J Cancer* 2012;131:E822-9.
  14. Kosaka T, Yamaki E, Mogi A, et al. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. *J Biomed Biotechnol* 2011;2011:165214.
  15. Carillio G, Montanino A, Costanzo R, et al. Cetuximab in non-small-cell lung cancer. *Expert Rev Anticancer Ther* 2012;12:163-75.
  16. Ibrahim EM, Abouelkhair KM, Al-Masri OA, et al. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. *Lung* 2011;189:193-8.
  17. Linardou H, Dahabreh IJ, Kanakoupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. *Lancet Oncol* 2008;9:962-72.
  18. Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. *Drugs* 2012;72:28-36.
  19. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. *Lung Cancer* 2010;69:272-8.
  20. Kwak E. The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. *Oncologist* 2011;16:1498-507.
  21. Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. *J Clin Oncol* 2011;29:2312-8.
  22. Hallqvist A, Wagenius G, Rylander H, et al. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite-*a* phase II study from the Swedish Lung Cancer Study Group. *Lung Cancer* 2011;71:166-72.
  23. Rothschild S, Bucher SE, Bernier J, et al. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. *Int J Radiat Oncol Biol Phys* 2011;80:126-32.
  24. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. *J Thorac Oncol* 2012;7:1315-26.
  25. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. *Oncologist* 2008;13:139-47.
  26. Papadimitrakopoulou VA, Soria JC, Jappe A, et al. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. *J Thorac Oncol* 2012;7:1594-601.
  27. Donev IS, Wang W, Yamada T, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. *Clin Cancer Res* 2011;17:2260-9.
  28. Niho S, Kunitoh H, Nokihara H, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. *Lung Cancer* 2012;76:362-7.
  29. Pallis AG, Syrigos KN. Targeting tumor neovasculature in non-small-cell lung cancer. *Crit Rev Oncol Hematol* 2013;86:130-42.
  30. Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. *J Clin Oncol* 2012;30:e104-8.
  31. Kimura H, Nakajima T, Takeuchi K, et al. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. *Lung Cancer* 2012;75:66-72.
  32. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol* 2012;13:1011-9.

**Cite this article as:** Domvri K, Darwiche K, Zarogoulidis P, Zarogoulidis K. Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. *Transl Lung Cancer Res* 2013;2(4):256-258. doi: 10.3978/j.issn.2218-6751.2012.12.06